Skip to main content
    T

    Trevi Therapeutics Inc (TRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.29
    -0.36 (-2.64%)

    Market Cap: $1.95B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Trevi Therapeutics Inc (TRVI) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Trevi Therapeutics (TRVI) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Trevi Therapeutics reported EPS of -$0.13, in line with the -$0.13 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(20/30)
    Avg Surprise
    +8.26%

    Upcoming Estimates

    Reports Mar 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.15
    Range-$0.18 - -$0.12
    14 analysts
    Revenue Consensus
    N/A
    RangeN/A
    12 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.16
    Range-$0.17 - -$0.15
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.160.0%
    60d ago-$0.160.0%
    30d ago-$0.160.0%
    7d ago-$0.160.0%
    Current-$0.16
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    TRVI has an expected report date of Mar 15, 2027.

    TRVI Earnings Call

    The latest TRVI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, TRVI beat 20, missed 7 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 40.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.13-$0.13-$0.18 - -$0.110.00%In lineN/A100 up, 1 downNov 9, 2026
    Jun 30, 2026-$0.11-$0.11-$0.13 - -$0.100.00%In lineN/A102 up, 1 downAug 6, 2026
    Mar 31, 2026-$0.09-$0.07-$0.10 - -$0.05-28.57%MissN/A10N/AMay 5, 2026
    Dec 31, 2025-$0.06-$0.10-$0.11 - -$0.08+39.09%BeatN/A94 up, 0 downMar 17, 2026
    Sep 30, 2025-$0.08-$0.10-$0.12 - -$0.09+20.00%BeatN/A81 up, 0 downNov 13, 2025
    Jun 30, 2025-$0.09-$0.10-$0.12 - -$0.08+10.00%BeatN/A81 up, 0 downAug 7, 2025
    Mar 31, 2025-$0.09-$0.12-$0.15 - -$0.10+25.00%BeatN/A6N/AMay 8, 2025
    Dec 31, 2024-$0.11-$0.12-$0.13 - -$0.11+6.06%BeatN/A71 up, 1 downMar 18, 2025
    Sep 30, 2024-$0.13-$0.11-$0.13 - -$0.09-18.18%MissN/A90 up, 0 downNov 6, 2024
    Jun 30, 2024-$0.12-$0.11-$0.11 - -$0.09-9.09%MissN/A51 up, 0 downAug 8, 2024
    Mar 31, 2024-$0.11-$0.09-$0.09 - -$0.08-22.22%MissN/A50 up, 0 downMay 7, 2024
    Dec 31, 2023-$0.08-$0.09-$0.11 - -$0.08+11.11%BeatN/A60 up, 0 downMar 20, 2024
    Sep 30, 2023-$0.08-$0.09-$0.10 - -$0.08+11.11%BeatN/A60 up, 0 downNov 9, 2023
    Jun 30, 2023-$0.07-$0.09-$0.10 - -$0.06+22.22%BeatN/A60 up, 0 downAug 10, 2023
    Mar 31, 2023-$0.06-$0.07-$0.09 - -$0.06+14.29%BeatN/A60 up, 0 downMay 11, 2023
    Dec 31, 2022-$0.06-$0.10-$0.13 - -$0.08+40.00%BeatN/A50 up, 0 downMar 16, 2023
    Sep 30, 2022-$0.12-$0.13-$0.18 - -$0.12+7.69%BeatN/A40 up, 0 downNov 10, 2022
    Jun 30, 2022-$0.14-$0.18N/A+22.22%BeatN/AN/A0 up, 0 downAug 11, 2022
    Mar 31, 2022-$0.24-$0.29-$0.31 - -$0.27+17.24%BeatN/A30 up, 0 downMay 12, 2022
    Dec 31, 2021-$0.28-$0.30-$0.34 - -$0.25+6.67%BeatN/A20 up, 0 downMar 17, 2022
    Sep 30, 2021-$0.34-$0.39-$0.46 - -$0.33+12.82%BeatN/A2N/ANov 10, 2021
    Jun 30, 2021-$0.49-$0.46-$0.46 - -$0.46-6.52%MissN/A2N/AAug 12, 2021
    Mar 31, 2021-$0.43-$0.52-$0.56 - -$0.49+17.31%BeatN/A3N/AMay 13, 2021
    Dec 31, 2020-$0.51-$0.44-$0.47 - -$0.41-15.91%MissN/A3N/AMar 25, 2021
    Sep 30, 2020-$0.41-$0.51-$0.67 - -$0.43+19.61%BeatN/A4N/ANov 12, 2020
    Jun 30, 2020-$0.41-$0.48-$0.52 - -$0.42+14.58%BeatN/A4N/AAug 13, 2020
    Mar 31, 2020-$0.48-$0.44-$0.46 - -$0.42-9.09%MissN/A4N/AMay 7, 2020
    Dec 31, 2019-$0.37-$0.51-$0.59 - -$0.44+27.45%BeatN/A4N/AMar 16, 2020
    Sep 30, 2019-$0.41-$0.47-$0.52 - -$0.44+12.77%BeatN/A4N/ANov 14, 2019
    Jun 30, 2019-$0.41-$0.41-$0.45 - -$0.360.00%In lineN/A4N/AAug 12, 2019
    Mar 31, 2019-$13.85-$0.52-$0.63 - -$0.29N/AN/AN/A4N/AMay 8, 2019
    Dec 31, 2018Not reportedN/AN/AN/ANot reportedN/AN/AN/AFeb 27, 2019
    Sep 30, 2018-$0.59N/AN/AN/AN/AN/AN/AN/ADec 21, 2018
    Last 33 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.32, after -$0.47 the year before. It was -$0.59 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.32N/A
    Dec 31, 2024-$0.47N/A
    Dec 31, 2023-$0.29N/A
    Dec 31, 2022-$0.56N/A
    Dec 31, 2021-$1.54N/A
    Dec 31, 2020-$1.81N/A
    Dec 31, 2019-$15.04N/A
    Dec 31, 2018-$0.59N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,85216
    2026Q1Mar 31, 20264,63613
    2025Q4Dec 31, 20256,60515
    2025Q3Sep 30, 20255,37512
    2025Q2Jun 30, 20255,49115
    2025Q1Mar 31, 20254,24212
    2024Q4Dec 31, 20244,75011
    2024Q3Sep 30, 20244,25210

    2026Q3 Earnings Call

    Opening remarks

    Jennifer Good President and CEO Good afternoon, and thank you for joining us for our third quarter 2026 earnings call and business update. Joining me today on this call are my colleagues, Dr. James Cassella, our Chief Development Officer; Farrell Simon, our Chief Commercial Officer; and David Hastings, our Chief Financial Officer. Dave and I will make some initial comments, and then the team is happy to answer any questions you may have. 2026 is a busy year of execution for the company, and the team is heads down on initiating and executing clinical trials in each of our programs. This includes activating sites globally, focusing on ensuring enrollment stays on track, all while staying aligned with the regulatory authorities. It has been fast-paced, but this is the fun part of what we do. Let me provide a brief update on each of our programs. First, our lead program in IPF-related chronic cough. We have initiated both OCEAN-1 and OCEAN-2 trials. We are now approved by all regulatory authorities in each of the countries in which we are conducting clinical trials, and the clinical team is focused on getting all the sites activated and screening patients. We will give an update once we reach 50% of the patients randomized in each of these trials. The trials are in early stages and progressing, and we continue to believe we are on track with our previously stated guidance for OCEAN-2, the 12-week study reading out in the second half of 2027, and OCEAN-1, the 24-week efficacy endpoint with 52 weeks of safety reading out in the first half of 2028. In October, we took an important step forward in our non-IPF-ILD cough program by aligning with the FDA on the development plan and next study. The pulmonary division has been very helpful and supportive as we think about how to get the first chronic cough drug approved in the U.S. The discussions have been collaborative and clear. Following this meeting with the FDA, our plan is to conduct a Phase II dose-ranging study with approximately 120 non-IPF-ILD patients to confirm the optimal dose or doses to take forward into Phase III. The protocol is written and will be submitted back to the FDA for any comments. We also have the wheels in motion, identifying sites and working with our CRO partner to prepare for study initiation. Recall that these clinical centers will overlap directly with the same sites we are using in our North American IPF Phase III program. When we signed a contract and negotiated budgets for our OCEAN trials, we planned for the fact that we likely would conduct an ILD trial. We are planning to initiate this trial in the first quarter of 2027.

    Frequently Asked Questions About TRVI

    When is Trevi Therapeutics's next earnings date?

    Trevi Therapeutics's next earnings report is expected for Mar 15, 2027.

    Did TRVI beat earnings estimates last quarter?

    Trevi Therapeutics reported EPS of -$0.13 for the quarter ended Sep 30, 2026, in line with the -$0.13 estimate.

    What EPS do analysts expect from TRVI next quarter?

    The consensus EPS estimate for Trevi Therapeutics for the quarter ending Dec 31, 2026 is -$0.15 from 14 analysts, with estimates from -$0.18 to -$0.12.

    How often does TRVI beat earnings estimates?

    Trevi Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +8.95%.